Abstract
Mycobacterium tuberculosis causes tuberculosis, one of the leading causes of fatal infectious diseases worldwide. Aminoglycosides, Amikacin (AK) & Kanamycin (KM) are commonly used in tuberculosis treatment and are drugs of choice especially for category II patients. They inhibit protein synthesis in susceptible bacteria by interacting with several steps of translation. Several explanations have been put forward to explain the mechanism of aminoglycoside resistance but still our knowledge is fragmentary. Rv0148 was found to be overexpressed in AK & KM resistant isolates. To establish the relationship of Rv0148 with AK & KM resistance it was cloned, expressed and antimicrobial drug susceptibility testing (DST) was carried out. Gene was cloned and expressed in E.coli BL21 using pQE2 expression vector. Etest results for drug susceptibility testing against AK & KM showed that the MIC of recombinant cells with Rv0148 was altered. Recombinants showed three fold changes in MIC with AK and two fold with KM E-strips. These MIC shifts speculate, overexpression of Rv0148 protein might be playing a pivotal role in the survival of mycobacteria by inhibiting/modulating the effects of AK & KM.
Keywords: Amikacin, Cloning & Expression, Etest, Kanamycin, Rv0148.
Current Proteomics
Title:Cloning, Expression and Correlation of Rv0148 to Amikacin & Kanamycin Resistance
Volume: 12 Issue: 2
Author(s): Divakar Sharma, Manju Lata, Mohammad Faheem, Asad Ullah Khan, Beenu Joshi, Krishnamurthy Venkatesan, Sangeeta Shukla and Deepa Bisht
Affiliation:
Keywords: Amikacin, Cloning & Expression, Etest, Kanamycin, Rv0148.
Abstract: Mycobacterium tuberculosis causes tuberculosis, one of the leading causes of fatal infectious diseases worldwide. Aminoglycosides, Amikacin (AK) & Kanamycin (KM) are commonly used in tuberculosis treatment and are drugs of choice especially for category II patients. They inhibit protein synthesis in susceptible bacteria by interacting with several steps of translation. Several explanations have been put forward to explain the mechanism of aminoglycoside resistance but still our knowledge is fragmentary. Rv0148 was found to be overexpressed in AK & KM resistant isolates. To establish the relationship of Rv0148 with AK & KM resistance it was cloned, expressed and antimicrobial drug susceptibility testing (DST) was carried out. Gene was cloned and expressed in E.coli BL21 using pQE2 expression vector. Etest results for drug susceptibility testing against AK & KM showed that the MIC of recombinant cells with Rv0148 was altered. Recombinants showed three fold changes in MIC with AK and two fold with KM E-strips. These MIC shifts speculate, overexpression of Rv0148 protein might be playing a pivotal role in the survival of mycobacteria by inhibiting/modulating the effects of AK & KM.
Export Options
About this article
Cite this article as:
Sharma Divakar, Lata Manju, Faheem Mohammad, Khan Ullah Asad, Joshi Beenu, Venkatesan Krishnamurthy, Shukla Sangeeta and Bisht Deepa, Cloning, Expression and Correlation of Rv0148 to Amikacin & Kanamycin Resistance, Current Proteomics 2015; 12(2) . https://dx.doi.org/10.2174/157016461202150903113053
DOI https://dx.doi.org/10.2174/157016461202150903113053 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Immune Cell-derived Vesicles: Modulators and Mediators of Inflammation
Current Pharmaceutical Design Mucosal Adjuvants
Current HIV Research subject Index To Volume 2
Current Drug Targets - Infectious Disorders Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets
Current Medicinal Chemistry Extrapulmonary Sarcoidosis: A Chameleon Disease at Imaging
Current Medical Imaging Do You See What I See: Recognition of Protozoan Parasites by Toll-Like Receptors
Current Immunology Reviews (Discontinued) Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy Microwave-Assisted Synthesis of Benzo-fused Seven-membered Azaheterocycles
Mini-Reviews in Organic Chemistry Polyfunctional Antibiotics Affecting Bacterial Membrane Dynamics
Anti-Infective Agents in Medicinal Chemistry Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Synthesis and Evaluation of Tetrazole-BasedHydrazone Derivatives Bearing a Pyridine Moiety as Antimicrobial Agents
Letters in Drug Design & Discovery Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders
Current Medicinal Chemistry Microbial Antigenic Pressure and Evolution of the Immune Response: Toward a Better Understanding of the Human Immune System in Health and Disease and Therapeutic Interventions
Endocrine, Metabolic & Immune Disorders - Drug Targets Virtual Screening on Natural Products for Discovering Active Compounds and Target Information
Current Medicinal Chemistry 2-Aminoimidazole, Glycociamidine and 2-Thiohydantoin-Marine Alkaloids as Molecular Inspirations for the Development of Lead Structures
Current Drug Targets Phenolics and Terpenoids; the Promising New Search for Anthelmintics: A Critical Review
Mini-Reviews in Medicinal Chemistry Nicotinamide Supplementation Protects Gestational Diabetic Rats by Reducing Oxidative Stress and Enhancing Immune Responses
Current Medicinal Chemistry State of the Art of Nanobiotechnology Applications in Neglected Diseases
Current Nanoscience Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials